0000950142-20-000050.txt : 20200106
0000950142-20-000050.hdr.sgml : 20200106
20200106133225
ACCESSION NUMBER: 0000950142-20-000050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200106
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Visioli Christopher
CENTRAL INDEX KEY: 0001735486
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-31191
FILM NUMBER: 20508998
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MEDICINES CO /DE
CENTRAL INDEX KEY: 0001113481
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043324394
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: 973-290-6000
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: MEDICINES CO/ MA
DATE OF NAME CHANGE: 20000504
4
1
es2000135_4-visioli.xml
OWNERSHIP DOCUMENT
X0306
4
2020-01-06
1
0001113481
MEDICINES CO /DE
MDCO
0001735486
Visioli Christopher
C/O THE MEDICINES COMPANY
8 SYLVAN WAY
PARSIPPANY
NJ
07054
0
1
0
0
Chief Financial Officer
Common Stock
2020-01-06
4
D
0
68843
D
0
D
Stock Option
29.01
2020-01-06
4
D
0
30000
0
D
Common Stock
30000
0
D
Stock Option
29.01
2020-01-06
4
D
0
24000
0
D
Common Stock
24000
0
D
Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"), without interest thereon and subject to any tax withholding.
Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option, less any required withholding taxes.
/s/ Stephen M. Rodin, Attorney-in-Fact for Christopher Visioli
2020-01-06